Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular…
Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarterNEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE)…
MINNEAPOLIS, MN, US, Nov. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTC ID: PETVW), through its wholly…
Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA…
NORTHVALE, NJ / ACCESS Newswire / November 14, 2025 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer…
Continues Execution of Strategic Transformation and Advancement of Biologics Pipeline FREMONT, CA / ACCESS Newswire / November 14, 2025 /…
~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to…
SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company…
- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments -- Dermata plans to launch…
Partnership integrates customized kitting, just-in-time operations, and nationwide distribution to accelerate decentralized and hybrid trials NEW BRUNSWICK, NEW JERSEY /…